Schaefer Ramon, Hernandez Diego, Selberg Lorenz, Schlander Michael
Division of Health Economics, German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany.
Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany.
J Comp Eff Res. 2021 Nov;10(16):1187-1195. doi: 10.2217/cer-2021-0047. Epub 2021 Sep 29.
To explore health technology assessment (HTA) outcomes of matched drug pairs by national agencies in Germany (Gemeinsamer Bundesausschuss, GBA), France (Haute Autorité de Santé, HAS) and England and Wales (NICE). We considered published GBA decisions, HAS reports and NICE guidance from January 2011 to June 2018. HTAs of matched pairs were compared overall, and for non-cancer and cancer drugs separately. We further analyzed the role of additional attributes related to cancer therapies. Matched pairs show higher concordance for GBA/HAS than for GBA/NICE and HAS/NICE. Overall, NICE evaluated technologies more favorably than GBA and HAS. GBA appraisals of cancer drugs, however, tended to be more positive than cancer-related recommendations by NICE and HAS. The findings indicate substantial variations in HTAs, although cancer-related outcomes seem to diverge less than non-cancer results.
为探究德国（联邦联合委员会，GBA）、法国（法国卫生管理局，HAS）以及英格兰和威尔士（英国国家卫生与临床优化研究所，NICE）等国家机构对配对药物的卫生技术评估（HTA）结果。我们研究了2011年1月至2018年6月期间已发布的GBA决策、HAS报告以及NICE指南。对配对药物的卫生技术评估进行了总体比较，并分别对非癌症药物和癌症药物进行了比较。我们进一步分析了与癌症治疗相关的其他属性的作用。配对药物在GBA/HAS之间的一致性高于GBA/NICE和HAS/NICE。总体而言，NICE对技术的评估比GBA和HAS更为有利。然而，GBA对癌症药物的评估往往比NICE和HAS的癌症相关建议更为积极。研究结果表明，卫生技术评估存在显著差异，尽管与癌症相关的结果差异似乎小于非癌症结果。
